120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
棕榈酰乙醇胺在肿瘤预防和治疗中的前景
Authors Pan Y , Wei P, Li Z, Wang J, Wang X
Received 26 June 2025
Accepted for publication 13 January 2026
Published 31 January 2026 Volume 2026:19 549752
DOI https://doi.org/10.2147/JIR.S549752
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Felix Marsh-Wakefield
Yuanming Pan,1– 3,* Panjian Wei,4,* Zhiqi Li,1 Jinghui Wang,1 Xiaomin Wang3
1Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China; 2School of Continuing Education, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China; 3Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, People’s Republic of China; 4Department of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yuanming Pan, Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing, 101149, People’s Republic of China, Tel/Fax +86-10-89509372, Email peterfpan2020@mail.ccmu.edu.cn Xiaomin Wang, Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Backstreet of Art Gallery, Dongcheng District, Beijing, 100010, People’s Republic of China, Email wangxiaomin_bhtcm@126.com
Abstract: Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that has garnered significant attention due to its potential multiple antitumor mechanisms. This review first explores the current statuses and challenges faced in tumor prevention and treatment, pointing out the toxic side effects of traditional chemotherapy and radiotherapy as well as the issue of drug resistance in tumor cells, particularly adverse reactions such as decreased immune function caused by chemotherapy and radiotherapy. It further analyzes the relationship between inflammation, immune evasion in the tumor microenvironment, and tumor growth and metastasis. Subsequently, it discusses multi-target therapy strategies, introducing PEA as an emerging therapeutic candidate whose anti-inflammatory, pro-apoptotic, anti-angiogenic, and antioxidant effects show great promise in tumor prevention and treatment. Preclinical research and preliminary clinical trial results indicate its safety and efficacy, supporting its role as an adjunct in tumor treatment. In addition, innovative explorations that combine modern drug delivery systems with combination therapy strategies are proposed, aiming to enhance the bioavailability and therapeutic effectiveness of PEA. Finally, the future of personalized precision treatment and combination therapy models is anticipated to bring new hope for tumor prevention and treatment.
Keywords: tumor prevention and treatment, palmitylethanolamide, multi-target therapy, anti-tumor mechanisms, clinical application
1Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China; 2School of Continuing Education, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China; 3Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, 100010, People’s Republic of China; 4Department of Clinical Laboratory, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yuanming Pan, Cancer Research Center, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing, 101149, People’s Republic of China, Tel/Fax +86-10-89509372, Email peterfpan2020@mail.ccmu.edu.cn Xiaomin Wang, Department of Oncology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23 Backstreet of Art Gallery, Dongcheng District, Beijing, 100010, People’s Republic of China, Email wangxiaomin_bhtcm@126.com
Abstract: Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that has garnered significant attention due to its potential multiple antitumor mechanisms. This review first explores the current statuses and challenges faced in tumor prevention and treatment, pointing out the toxic side effects of traditional chemotherapy and radiotherapy as well as the issue of drug resistance in tumor cells, particularly adverse reactions such as decreased immune function caused by chemotherapy and radiotherapy. It further analyzes the relationship between inflammation, immune evasion in the tumor microenvironment, and tumor growth and metastasis. Subsequently, it discusses multi-target therapy strategies, introducing PEA as an emerging therapeutic candidate whose anti-inflammatory, pro-apoptotic, anti-angiogenic, and antioxidant effects show great promise in tumor prevention and treatment. Preclinical research and preliminary clinical trial results indicate its safety and efficacy, supporting its role as an adjunct in tumor treatment. In addition, innovative explorations that combine modern drug delivery systems with combination therapy strategies are proposed, aiming to enhance the bioavailability and therapeutic effectiveness of PEA. Finally, the future of personalized precision treatment and combination therapy models is anticipated to bring new hope for tumor prevention and treatment.
Keywords: tumor prevention and treatment, palmitylethanolamide, multi-target therapy, anti-tumor mechanisms, clinical application